Search Results for "Surgery"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Surgery. Results 51 to 60 of 252 total matches.
Intravenous Acetaminophen (Ofirmev)
The Medical Letter on Drugs and Therapeutics • Apr 04, 2011 (Issue 1361)
surgery in 244 patients, IV acetaminophen
650 mg every 4 hours significantly
reduced pain and rescue use ...
The FDA has approved an intravenous (IV) formulation
of acetaminophen (Ofirmev – Cadence) for use in
patients ≥2 years old for management of pain either as
monotherapy (mild to moderate pain) or with an opioid
(moderate to severe pain) and for reduction of fever.
Uterine Artery Embolization for Fibroids
The Medical Letter on Drugs and Therapeutics • Apr 11, 2005 (Issue 1206)
Publication
SUMMARY – UAE is an alternative to surgery for treatment of uterine fibroids that uses injections ...
Uterine artery embolization (UAE) is an increasingly used alternative to surgery for treatment of uterine fibroids.
Obalon Balloon System - Another Gastric Balloon for Weight Loss
The Medical Letter on Drugs and Therapeutics • Jun 19, 2017 (Issue 1523)
nerve signals between
the stomach and the brain, is less effective than bariatric
surgery.3 ...
The FDA has approved the Obalon Balloon System
(Obalon), a swallowable intragastric gas-filled balloon
device, to facilitate weight loss in adults with a body
mass index (BMI) of 30-40 kg/m2 who have not been
able to lose weight through diet and exercise. Two
other gastric balloon devices, ReShape and Orbera,
were approved earlier.
Maestro Rechargeable System for Weight Loss
The Medical Letter on Drugs and Therapeutics • Apr 25, 2016 (Issue 1493)
and
intra-abdominal surgery occurred in 8.6% of patients.4
Pain at the neuroregulator site occurred ...
The FDA has approved the Maestro Rechargeable
System (EnteroMedics), a subcutaneously implanted
device, for use in adults who have not been able to lose
weight with a weight loss program within the past 5 years
and who have a body mass index (BMI) of 40 to 45, or a
BMI ≥35 and at least one obesity-related comorbidity.
ReShape and Orbera - Two Gastric Balloon Devices for Weight Loss
The Medical Letter on Drugs and Therapeutics • Aug 31, 2015 (Issue 1476)
.
CONTRAINDICATIONS — Both devices are contraindicated
in patients who have had gastrointestinal
surgery or open ...
The FDA has approved the ReShape Integrated Dual
Balloon System (ReShape Medical) and the Orbera
Intragastric Balloon System (Apollo Endosurgery) for
up to 6 months of use in adults with a BMI of 30-40
who have not been able to maintain weight loss with
a weight loss program and, for ReShape, who have at
least one obesity-related comorbidity. Both devices
have been available in the European Union and
elsewhere for years (20 years for Orbera). Three other
devices, the LAP-Band, the Realize adjustable gastric band, and the Maestro Rechargeable System, are FDA-approved
for long-term...
Ciprofloxacin (Otiprio) for Tympanostomy Tube Insertion
The Medical Letter on Drugs and Therapeutics • May 23, 2016 (Issue 1495)
as otorrhea ≥3
days after surgery, need for antibiotics for any reason
at any time post-surgery, or a missed ...
The FDA has approved ciprofloxacin 6% otic
suspension (Otiprio – Otonomy) for single-dose
prophylaxis in children with bilateral otitis media
with effusion who are undergoing tympanostomy
tube placement. It is the first drug to be approved
for this indication in the US. Otic formulations
of the fluoroquinolone antibiotics ofloxacin
(Floxin Otic, and generics) and ciprofloxacin (plus
dexamethasone; Ciprodex) have been available for
years for treatment of acute otitis media in children
with tympanostomy tubes; an otic suspension
containing ciprofloxacin and fluocinolone...
Desflurane - A New Volatile Anesthetic
The Medical Letter on Drugs and Therapeutics • Apr 30, 1993 (Issue 895)
of desflurane can be changed rapidly as
stimulus levels change during surgery. In one study, recovery took ...
Desflurane (Suprane - Anaquest), an inhalation anesthetic, has been approved by the US Food and Drug Administration for induction and maintenance of general anesthesia in adults and for maintenance of anesthesia in infants and children. Like isoflurane (Forane), the last volatile anesthetic to become available in the USA (Medical Letter, 23:112, 1981), the new agent is a halogenated methyl ethyl ether, differing from isoflurane in the substitution of a fluorine for a chlorine atom.
Cosmetic Phalloplasty
The Medical Letter on Drugs and Therapeutics • May 24, 2004 (Issue 1183)
reconstructive surgery for these complications
(H Wessells et al, J Urol 1996; 155:1617; GJ Alter J Urol 1997 ...
Some patients may be asking healthcare providers about the surgical techniques to enlarge the penis that are widely promoted on the Internet. Phalloplasty was first used to treat traumatic or surgical amputation (for cancer), epispadias and Peyronie's disease (JP Yurkanin et al, J Urol 2001; 166:1769).
In Brief: New FDA Warning of Pulmonary Aspiration with GLP-1 Receptor Agonists
The Medical Letter on Drugs and Therapeutics • Dec 23, 2024 (Issue 1718)
recommended
withholding GLP-1 receptor agonists on the day
of elective surgery for those ...
The package inserts of the GLP-1 receptor agonists
dulaglutide (Trulicity), exenatide (Byetta, Bydureon
BCise), liraglutide (Saxenda, Victoza), and semaglutide
(Ozempic, Rybelsus, Wegovy) and the dual glucosedependent
insulinotropic polypeptide (GIP)/GLP-1
receptor agonist tirzepatide (Mounjaro, Zepbound)
have been updated to include rare postmarketing
reports of pulmonary aspiration associated with their
use in patients undergoing elective surgery or other
procedures requiring general anesthesia or deep
sedation who had residual gastric contents despite
preoperative...
Med Lett Drugs Ther. 2024 Dec 23;66(1718):201-2 doi:10.58347/tml.2024.1718a | Show Introduction Hide Introduction
Enoxaparin - A Low-Molecular-Weight Heparin
The Medical Letter on Drugs and Therapeutics • Aug 20, 1993 (Issue 903)
-analysis of studies involving more than 8000
patients undergoing orthopedic surgery found ...
Enoxaparin (Lovenox - Rh ne-Poulenc Rorer), the first low-molecular-weight heparin to become commercially available in the USA, was recently approved by the US Food and Drug Administration for prevention of deep vein thrombosis following hip replacement. Five other products have been marketed in Europe.